jay
fishman
sylvia
f
costa
barbara
alexand
success
manag
infect
kidney
transplant
recipi
function
immun
statu
host
epidemiolog
infecti
exposur
transplant
recipi
suscept
broad
spectrum
infecti
pathogen
manifest
diminish
sign
symptom
invas
infect
thu
diagnosi
infect
difficult
transplant
recipi
immunolog
normal
individu
interact
infect
immunosuppress
immun
function
often
result
clinic
syndrom
reflect
multipl
simultan
process
infect
graft
reject
immunocompromis
patient
toler
invas
infect
poorli
high
morbid
mortal
lend
urgenc
need
earli
specif
diagnosi
guid
antimicrobi
therapi
given
predomin
tlymphocyt
dysfunct
inher
transplant
immunosuppress
viral
infect
major
contributor
morbid
result
graft
dysfunct
graft
reject
system
ill
increas
risk
opportunist
infect
eg
pneumocysti
aspergillu
viral
mediat
cancer
risk
infect
kidney
transplant
recipi
determin
interact
two
key
factor
epidemiolog
exposur
patient
includ
time
intens
virul
organ
encount
patient
net
state
immunosuppress
conceptu
measur
factor
contribut
host
risk
infect
import
infecti
exposur
determin
abil
host
deal
effect
pathogen
thu
immunosuppress
diabet
vascular
diseas
greater
risk
bacteri
skin
infect
compar
immunosuppress
nondiabet
understand
risk
factor
transplant
recipi
allow
develop
differenti
diagnosi
infecti
syndrom
develop
prevent
strategi
prophylaxi
vaccin
appropri
individu
uniqu
risk
epidemiolog
exposur
import
transplant
recipi
divid
four
overlap
categori
donorderiv
infect
recipientderiv
infect
communityderiv
exposur
nosocomi
exposur
tabl
divers
donorderiv
infect
recogn
transplant
recipi
infect
latent
eg
viral
parasit
wherea
other
activ
eg
bacteremia
fungemia
donor
time
procur
frequent
pathogen
endem
organ
caus
signific
morbid
recipi
form
basi
screen
paradigm
organ
donor
bloodstream
infect
bacteria
yeast
donor
time
donat
caus
local
abscess
system
infect
importantli
may
adher
anastomot
site
vascular
urinari
produc
leak
mycot
aneurysm
transmiss
donorderiv
viral
infect
common
expect
includ
cytomegaloviru
cmv
epsteinbarr
viru
ebv
associ
specif
syndrom
transplant
recipi
see
section
select
infect
import
greatest
risk
viral
infect
transmiss
seroposit
donor
latent
infect
seroneg
immunolog
recipi
virus
demonstr
acceler
progress
lymphocyt
choriomening
viru
lcmv
rabi
west
nile
viru
wnv
transplant
recipi
latent
infect
tuberculosi
toxoplasmosi
strongyloidiasi
may
activ
mani
year
initi
often
unrecogn
exposur
donor
screen
transplant
limit
avail
technolog
time
constraint
within
organ
deceas
donor
must
use
discuss
later
routin
screen
donor
reli
histori
antibodi
detect
serolog
test
nucleic
acid
test
nat
common
infect
risk
factor
infect
donor
often
unknown
result
transmiss
may
occur
seroneg
donor
activ
viral
exposur
seroconvers
window
period
viral
load
limit
detect
nat
select
risk
demonstr
cluster
donorderiv
trypanosoma
cruzi
chaga
diseas
rabi
viru
wnv
lcmv
infect
organ
transplant
recipi
nat
donor
screen
eg
human
immunodefici
viru
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
wnv
capac
reduc
window
period
exposur
pathogen
detect
serolog
test
albeit
risk
falseposit
assay
given
heighten
assay
sensit
given
risk
transmiss
infect
organ
donor
recipi
certain
syndrom
consid
rel
contraind
organ
donat
kidney
transplant
typic
elect
surgeri
reason
avoid
donat
individu
unexplain
fever
rash
infecti
syndrom
includ
mening
enceph
center
transplant
donor
untreat
hcv
hiv
hivposit
recipi
infect
undertaken
common
criteria
exclus
organ
donor
list
tabl
recipientderiv
exposur
gener
reflect
colon
latent
infect
reactiv
immunosuppress
certain
common
infect
recogn
evalu
transplant
candid
includ
hbv
hcv
hiv
necessari
obtain
care
histori
prior
infect
travel
exposur
guid
prevent
strategi
empir
therapi
notabl
among
infect
mycobacteri
infect
includ
tuberculosi
strongyloidiasi
viral
infect
herp
simplex
viru
hsv
varicellazost
viru
vzv
shingl
histoplasmosi
coccidioidomycosi
paracoccidiomycosi
fig
vaccin
statu
evalu
childhood
vaccin
tetanu
hbv
influenza
pneumococcu
vaccin
previous
administ
consid
advanc
transplant
immun
respons
like
robust
live
viru
vaccin
gener
contraind
transplant
tabl
dietari
habit
also
consid
includ
use
well
water
cryptosporidium
consumpt
uncook
meat
salmonella
listeria
hepat
e
unpasteur
dairi
product
listeria
common
exposur
commun
often
relat
contamin
food
water
ingest
exposur
infect
famili
member
cowork
exposur
relat
hobbi
travel
work
infect
caus
common
respiratori
virus
influenza
parainfluenza
respiratori
syncyti
viru
rsv
adenoviru
metapneumoviru
atyp
pathogen
hsv
carri
risk
viral
pneumonia
increas
risk
bacteri
fungal
superinfect
commun
contact
transfusionassoci
exposur
cmv
ebv
may
produc
sever
primari
infect
nonimmun
host
recent
remot
exposur
endem
geograph
restrict
system
mycos
blastomyc
dermatitidi
coccidioid
immiti
histoplasma
capsulatum
paracoccidioid
brasiliensi
mycobacterium
tuberculosi
result
local
pulmonari
system
metastat
infect
asymptomat
strongyloid
stercorali
infect
may
activ
year
initi
exposur
result
immunosuppress
therapi
see
fig
reactiv
result
either
diarrheal
ill
parasit
migrat
hyperinfect
syndrom
character
hemorrhag
enterocol
hemorrhag
pneumonia
dissemin
infect
accompani
usual
gramneg
polymicrobi
bacteremia
mening
gastroenter
secondari
salmonella
cryptosporidium
varieti
enter
virus
eg
noroviru
result
persist
infect
sever
prolong
diarrheal
diseas
increas
risk
primari
secondari
bloodstream
invas
metastat
infect
nosocomi
infect
increas
import
organ
signific
multidrug
antimicrobi
resist
mdro
present
medic
center
includ
enterococci
resist
vancomycin
linezolid
daptomycin
andor
quinupristindalfopristin
methicillinresist
staphylococci
gramneg
bacteria
produc
extendedspectrum
betalactamas
esbl
carbapenemas
cre
fluconazoleresist
candida
speci
see
tabl
singl
case
nosocomi
aspergillu
infect
immunocompromis
host
absenc
clear
epidemiolog
exposur
view
failur
infect
control
practic
antimicrobi
misus
inadequ
infect
control
practic
caus
increas
rate
clostridium
difficil
coliti
outbreak
infect
secondari
legionella
associ
hospit
plumb
contamin
water
suppli
ventil
system
nosocomi
spread
pneumocysti
jirovecii
immunocompromis
patient
document
respiratori
viral
infect
may
acquir
medic
staff
consid
among
caus
fever
respiratori
decompens
hospit
institution
immunocompromis
individu
nosocomi
acquir
infect
investig
ascertain
sourc
prevent
subsequ
infect
net
state
immunosuppress
conceptu
measur
risk
factor
infect
individu
includ
immunosuppress
medic
iatrogen
condit
tabl
among
import
follow
specif
immunosuppress
therapi
includ
dose
durat
sequenc
agent
tabl
technic
difficulti
transplant
result
increas
incid
leak
blood
lymph
urin
fluid
collect
devit
tissu
poor
wound
heal
prolong
use
surgic
drainag
cathet
prolong
instrument
includ
airway
intub
use
vascular
access
devic
eg
dialysi
cathet
prolong
use
broadspectrum
antibiot
renal
hepat
dysfunct
addit
graft
dysfunct
presenc
infect
immunomodul
viru
includ
cmv
ebv
hbv
hcv
hiv
specif
immunosuppress
agent
associ
increas
risk
certain
infect
see
tabl
assess
overal
degre
immun
compromis
remain
difficult
combin
organ
dysfunct
immunosuppress
viral
infect
nutrit
statu
technic
factor
factor
infecti
risk
resist
quantif
measur
pathogenspecif
ie
cellular
immun
function
use
guid
prophylaxi
specif
infect
individu
commerci
assay
exist
cmv
tuberculosi
includ
assay
igra
elispot
major
histocompat
complex
mhc
tetram
stain
intracellular
cytokin
stain
low
serum
antibodi
level
correl
overal
risk
infect
specif
cutoff
valu
indic
replac
therapi
lack
data
exist
function
immun
reconstitut
tor
blymphocyt
deplet
costimulatori
blockad
recent
data
support
import
genet
polymorph
among
transplant
recipi
risk
microbi
colon
infect
standard
immunosuppress
regimen
common
infect
vari
predict
pattern
depend
time
elaps
sinc
transplant
fig
primarili
reflect
chang
risk
factor
time
includ
surgeri
hospit
taper
immunosuppress
acut
chronic
reject
exposur
infect
commun
predict
pattern
infect
chang
alter
immunosuppress
regimen
eg
increas
steroid
graft
reject
intercurr
viral
infect
neutropenia
drug
toxic
graft
dysfunct
signific
epidemiolog
exposur
travel
food
timelin
remain
use
start
point
differenti
diagnosi
infect
transplant
although
alter
introduct
new
immunosuppress
agent
pattern
use
includ
reduc
use
corticosteroid
calcineurin
inhibitor
increas
use
antibodybas
induct
therapi
sirolimu
routin
antimicrobi
prophylaxi
improv
molecular
assay
antimicrobi
resist
transplant
hivinfect
hcvinfect
individu
broader
epidemiolog
exposur
work
travel
three
overlap
period
risk
infect
transplant
see
fig
associ
differ
pattern
common
pathogen
follow
periop
period
approxim
week
transplant
reflect
surgic
technic
complic
nosocomi
exposur
period
month
transplant
depend
rapid
taper
immunosuppress
use
antilymphocyt
induct
therapi
deploy
prophylaxi
reflect
intens
immunosuppress
viral
activ
opportunist
infect
period
beyond
first
year
transplant
reflect
communityacquir
exposur
unusu
pathogen
base
level
mainten
immunosuppress
timelin
use
varieti
way
establish
differenti
diagnosi
transplant
patient
suspect
infect
provid
clue
presenc
excess
environment
hazard
individu
either
within
hospit
commun
serv
guid
design
prevent
antimicrobi
strategi
infect
occur
outsid
usual
period
unusu
sever
suggest
either
intens
epidemiolog
exposur
excess
immunosuppress
prevent
infect
must
link
risk
infect
variou
time
transplant
tabl
outlin
routin
prevent
strategi
keep
mind
strategi
serv
delay
onset
infect
face
epidemiolog
pressur
use
antimicrobi
prophylaxi
vaccin
behavior
modif
eg
routin
hand
wash
advic
dig
garden
without
mask
may
result
shift
right
infect
timelin
unless
intens
immunosuppress
reduc
immun
develop
first
month
transplant
three
type
infect
occur
first
infect
colon
present
recipi
transplant
emerg
set
surgeri
immunosuppress
pretransplant
pneumonia
vascular
access
infect
common
exampl
type
infect
colon
recipi
resist
organ
infect
intraven
cathet
surgic
drain
also
common
eg
methicillinresist
staphylococcu
aureu
mrsa
infect
control
erad
degre
possibl
transplant
donor
eg
line
infect
contamin
organ
procur
process
activ
infect
may
transmit
donor
recipi
emerg
earlier
normal
predict
eg
hsv
tuberculosi
histoplasmosi
recent
cluster
donorderiv
infect
result
unfortun
timinga
donor
acquir
acut
infect
hiv
wnv
rabi
lcmv
unrel
caus
death
third
common
sourc
infect
earli
period
relat
transplant
procedur
infect
includ
surgic
wound
infect
pneumonia
aspir
bacteremia
associ
vascular
access
surgic
drainag
cathet
urinari
tract
infect
superinfect
fluid
collectionsleak
vascular
urinari
anastomos
lymphocel
nosocomi
infect
may
carri
antimicrobialresist
pathogen
observ
nonimmunosuppress
patient
undergo
compar
surgeri
given
immunosuppress
sign
infect
may
subtl
sever
durat
usual
increas
thu
bowel
perfor
may
clinic
silent
mark
tachycardia
rise
white
blood
cell
count
abnorm
liver
function
test
graft
dysfunct
technic
skill
surgeon
meticul
postop
care
ie
wound
care
proper
mainten
time
remov
endotrach
tube
vascular
access
devic
drainag
cathet
determin
degre
risk
infect
anoth
import
infect
period
clostridium
difficil
coliti
limit
periop
antibiot
prophylaxi
ie
singl
dose
hour
antibiot
cefazolin
amoxicillinclavulan
usual
adequ
renal
transplant
addit
coverag
requir
known
risk
factor
eg
prior
colon
mrsa
pancrea
transplant
addit
periop
prophylaxi
patient
proven
toler
tmpsmx
altern
regimen
includ
combin
atovaquon
mg
oral
daili
meal
plu
levofloxacin
mg
oral
daili
equival
fluoroquinolon
without
anaerob
activ
pentamidin
mg
intraven
inhal
everi
week
dapson
mg
oral
daili
twice
weekli
without
pyrimethamin
agent
toxic
must
consid
eg
hemolysi
host
dapson
none
altern
program
offer
broad
protect
tmpsmx
altern
valganciclovir
high
dose
valacyclovir
gday
complianc
difficult
efficaci
well
studi
po
ganciclovir
gday
lower
bioavail
first
dose
ganciclovir
often
intraven
valganciclovir
may
use
take
oral
medic
antivir
agent
adjust
renal
function
abnorm
renal
function
formal
creatinin
clearanc
measur
may
indic
dose
antivir
therapi
gener
reduc
neutropenia
consid
option
first
antifung
prophylaxi
mucocutan
candidiasi
prevent
oral
clotrimazol
nystatin
time
per
day
corticosteroid
therapi
face
broadspectrum
antibacteri
therapi
diabet
transplant
patient
fluconazol
mgday
day
use
treat
prophylaxi
failur
routin
prophylaxi
fluconazol
use
pancrea
kidneypancrea
transplant
prophylaxi
determin
base
presenc
absenc
colon
risk
factor
fungal
infect
hybrid
prophylaxi
mani
center
prefer
univers
prophylaxi
highest
risk
kidney
recipi
r
lymphocyt
deplet
preemptiv
therapi
lower
risk
group
b
preemptiv
therapi
preemptiv
therapi
requir
care
organ
monitor
program
patient
complianc
either
molecular
cmv
viral
load
test
antigenemia
assay
may
use
monitor
monitor
perform
weekli
transplant
week
infect
indic
posit
assay
treat
either
oral
valganciclovir
intraven
ganciclovir
therapi
continu
least
viremia
undetect
donor
serolog
r
recipi
serolog
nat
nucleic
acid
test
normal
world
health
organ
intern
standard
yeast
use
fluconazol
mind
potenti
increas
sirolimu
calcineurin
inhibitor
level
use
concomitantli
azol
antifung
agent
opportunist
infect
notabl
absent
first
month
transplant
even
though
daili
dose
immunosuppress
drug
may
greatest
time
implic
observ
import
suggest
daili
dose
immunosuppress
drug
less
import
cumul
dose
ie
area
curv
determin
true
state
immunosuppress
net
state
immunosuppress
first
month
transplant
great
enough
support
opportunist
infect
unless
exposur
excess
accordingli
occurr
singl
case
opportunist
infect
period
trigger
epidemiolog
investig
environment
hazard
second
phase
infect
tradit
month
extend
two
main
factor
success
use
prophylaxi
monitor
program
target
cmv
herpesvirus
pneumocysti
urinari
tract
infect
hbv
intensif
immunosuppress
use
potent
agent
antibodybas
induct
therapi
prolong
effect
immun
function
see
tabl
infect
transplant
recipi
month
transplant
one
three
caus
period
stage
also
set
emerg
subgroup
patientsth
chronic
neer
well
patient
requir
higher
usual
level
immunosuppress
maintain
graft
function
poor
technic
outcom
transplant
leak
vascular
issu
poor
graft
function
persist
viral
infect
eg
c
difficil
coliti
predict
longterm
suscept
infect
third
phase
discuss
next
patient
may
benefit
prolong
lifelong
prophylaxi
antibacteri
antifung
antivir
combin
prevent
lifethreaten
infect
opportunist
infect
reflect
immunosuppress
regimen
use
individu
epidemiolog
presenc
absenc
immunomodul
viral
infect
viral
pathogen
reject
respons
febril
episod
occur
period
anticmv
strategi
trimethoprimsulfamethoxazol
tmpsmx
prophylaxi
effect
decreas
risk
infect
tmpsmx
prophylaxi
effect
prevent
pneumocysti
pneumonia
reduc
incid
urinari
tract
infect
urosepsi
l
monocytogen
mening
nocardia
speci
infect
gondii
recipi
underw
transplant
year
previous
divid
three
group
term
infecti
risk
transplant
recipi
technic
good
procedur
satisfactori
allograft
function
reduc
immunosuppress
absenc
chronic
viral
infect
patient
resembl
gener
commun
term
infect
risk
communityacquir
respiratori
virus
constitut
major
risk
occasion
patient
develop
primari
cmv
infect
social
acquir
infect
relat
underli
diseas
eg
skin
infect
diabet
second
group
patient
chronic
viral
infect
may
produc
end
organ
damag
eg
bk
polyomaviru
lead
fibrosi
hcv
lead
cryoglobulinemia
cirrhosi
cmv
chronic
graft
reject
malign
eg
posttransplant
lymphoprolif
diseas
ptld
secondari
ebv
skin
anogenit
cancer
relat
papillomavirus
absenc
specif
effect
antivir
therapi
patient
often
suffer
graft
reject
reduc
intens
immunosuppress
third
group
patient
unsatisfactori
allograft
function
suffer
ravag
renal
dysfunct
often
despit
intensifi
immunosuppress
use
preserv
graft
function
declin
allograft
function
may
result
underli
diseas
progress
atherosclerosi
iga
diabet
calcineurin
inhibitor
toxic
humor
cellular
graft
reject
thu
patient
overimmunosuppress
rel
risk
infect
patient
may
benefit
lifetim
mainten
tmpsmx
often
fluconazol
prophylaxi
group
one
also
consid
organ
commonli
associ
immun
dysfunct
acquir
immunodefici
syndrom
aid
bartonella
rhodococcu
cryptosporidium
microsporidia
invas
fungal
pathogen
aspergillu
mucoral
dematiac
pigment
mold
even
minim
clinic
sign
symptom
warrant
care
evalu
group
highrisk
patient
guidelin
pretranspl
screen
subject
sever
public
includ
consensu
confer
immunocompromis
host
societi
american
societi
transplant
clinic
practic
guidelin
evalu
kidney
transplant
candid
american
societi
transplant
surgeon
clinic
practic
guidelin
evalu
live
kidney
transplant
donor
transplant
donor
crucial
challeng
screen
deceas
organ
donor
narrow
time
frame
evalu
use
organ
must
procur
implant
microbiolog
assess
complet
thu
bacteremia
fungemia
may
detect
transplant
perform
infect
gener
result
transmiss
infect
infect
adequ
treat
procur
use
antimicrobi
agent
organ
suscept
appropri
durat
recipi
tissu
bacterem
donor
mean
day
effect
therapi
transplant
prevent
transmiss
suscept
pathogen
era
reduc
antimicrobi
resist
surveil
addit
cours
therapi
recipi
employ
target
known
donorderiv
pathogen
bacteri
mening
must
treat
antibiot
penetr
cerebrospin
fluid
organ
procur
individu
unidentifi
untreat
caus
meningoenceph
sepsi
use
organ
donor
donorderiv
infect
caus
candida
speci
result
organ
contamin
candidemia
time
procur
suscept
test
isol
prolong
treatment
week
effect
agent
avoid
pyelonephr
abscess
format
mycot
aneurysm
candidemia
recipi
recommend
vascular
involv
candida
speci
recipi
requir
least
week
therapi
certain
activ
infect
cmv
vzv
hsv
ebv
hcv
may
unsuspect
even
seroposit
donor
requir
nat
diagnosi
likewis
donor
clinic
social
medic
histori
essenti
reduc
risk
infect
known
infect
treat
procur
possibl
see
previou
discuss
unrecogn
donor
pathogen
major
exclus
criteria
outlin
tabl
live
donor
procedur
consid
elect
evalu
complet
infect
treat
donat
interim
histori
must
taken
time
surgeri
assess
presenc
new
infect
sinc
initi
donor
evalu
intercurr
infect
flulik
ill
headach
confus
myalgia
cough
might
harbing
import
infect
wnv
sever
acut
respiratori
syndrom
sar
trypanosoma
cruzi
live
donor
undergo
batteri
serolog
test
tabl
purifi
protein
deriv
ppd
skin
test
tuberculosi
releas
assay
indic
chest
radiograph
test
must
individu
base
uniqu
risk
factor
eg
travel
note
kidney
transplant
recipi
exclus
urinari
tract
infect
includ
bacteria
yeast
bacteremia
time
donat
us
public
health
servic
suggest
rescreen
potenti
donor
close
donat
feasibl
use
nat
hiv
hcv
hbv
tuberculosi
mycobacterium
tuberculosi
donor
repres
approxim
report
posttranspl
tuberculosi
case
much
higher
rate
occur
endem
region
activ
diseas
exclud
ppdposit
donor
chest
radiograph
sputum
cultur
chest
comput
tomographi
ct
chest
radiograph
abnorm
urin
acidfast
bacillu
cultur
may
use
ppdposit
kidney
donor
isoniazid
prophylaxi
recipi
consid
untreat
ppdposit
donor
factor
favor
prophylaxi
includ
donor
endem
region
highrisk
social
environ
use
highdos
steroid
regimen
recipi
parasit
chaga
diseas
trypanosoma
cruzi
transmit
transplant
endem
area
recent
us
schistosomiasi
strongyloid
stercorali
gener
recipientderiv
malaria
leishmaniasi
rare
transmit
allograft
ebv
infect
major
risk
develop
ptld
risk
greatest
ebvseroneg
recipi
ebvseroposit
allograft
ie
donor
seroposit
recipi
seroneg
situat
common
pediatr
transplant
recipi
atrisk
group
includ
adult
coinfect
cmv
receiv
greater
intens
immunosuppress
notabl
cell
deplet
possibl
belatacept
monitor
consid
atrisk
individu
use
quantit
molecular
assay
ebv
ebv
also
cofactor
lymphoid
malign
vzv
screen
use
identifi
seroneg
individu
histori
chickenpox
shingl
vaccin
transplant
like
although
unstudi
new
herp
zoster
subunit
vaccin
replac
live
vaccin
transplant
hsv
screen
perform
center
although
activ
infect
prevent
anticmv
prophylaxi
except
newer
agent
maribavir
letermovir
posttranspl
period
vzv
serolog
statu
particularli
import
nonimmun
children
may
expos
school
antivir
vzv
immunoglobulin
prophylaxi
adult
atyp
present
infect
pneumonia
gastrointestin
diseas
herpesvirus
also
may
reactiv
serv
cofactor
cmv
fungal
infect
kaposi
sarcomaassoci
herpesviru
caus
malign
notabl
endem
region
south
america
surround
mediterranean
basin
hepat
screen
chang
quantit
nucleic
acid
test
qnat
screen
advent
effect
antivir
therapi
hbv
surfac
antigen
hbsag
hbv
core
antibodi
hbcab
use
screen
purpos
see
chapter
detail
discuss
posit
hbv
surfac
antibodi
titer
indic
either
vaccin
prior
infect
hbcabigm
posit
suggest
activ
hbv
infect
wherea
igg
posit
suggest
remot
persist
infect
hbsagneg
hbcabiggposit
donor
viral
dna
liver
may
appropri
kidney
donor
hbvinfect
vaccin
thu
immun
renal
recipi
quantit
viral
assay
hbv
obtain
guid
therapi
presenc
hbsagneg
hbcabiggposit
assay
may
falseposit
result
reflect
true
latent
hbv
infect
effect
hcv
infect
chang
era
directli
activ
antivir
agent
daa
evid
exist
use
hcvposit
kidney
clinic
benefit
recipi
pangenotyp
daa
therapi
cure
hcv
infect
transplant
untreat
hcv
infect
progress
cirrhosi
rapidli
immunosuppress
cmv
coinfect
see
chapter
detail
discuss
side
effect
histor
therapi
pegyl
ribavirin
increas
transplant
popul
hcv
therapi
initi
base
centerspecif
protocol
may
reli
quantit
nat
hcv
ribonucl
acid
rna
liver
function
test
see
chapter
histor
progress
untreat
hiv
infect
transplant
recipi
rapid
howev
hivinfect
kidney
organ
transplant
hivinfect
recipi
south
africa
elsewher
us
hiv
organ
polici
equiti
hope
act
organ
hivinfect
donor
may
transplant
hiv
recipi
part
clinic
trial
inform
consent
first
plan
hivhiv
transplant
us
perform
march
base
current
criteria
recipi
hiv
infect
donor
evalu
base
epidemiolog
use
fourthgener
enzymelink
immunosorb
assay
elisa
nat
test
human
cell
lymphotrop
viru
htlvi
endem
caribbean
part
asia
japan
progress
htlviassoci
myelopathytrop
spastic
paraparesi
adult
cell
leukemialymphoma
htlvii
serolog
crossreact
htlvi
less
clearli
associ
diseas
use
organ
donor
gener
avoid
howev
serolog
test
distinguish
two
type
viru
donor
screen
htlv
us
longer
mandatori
center
continu
donor
screen
endem
region
use
target
screen
donor
perceiv
high
risk
wnv
flaviviru
associ
viral
syndrom
meningoenceph
may
transmit
blood
transfus
organ
transplant
routin
screen
donor
advoc
area
endem
infect
donor
unexplain
chang
mental
statu
recent
viral
ill
neurolog
sign
avoid
pretranspl
period
use
obtain
travel
anim
environment
exposur
histori
updat
immun
counsel
recipi
regard
travel
food
infect
risk
ongo
infect
must
erad
degre
possibl
transplant
two
form
infect
pose
special
riskbloodstream
infect
relat
vascular
access
includ
dialysi
pneumonia
put
patient
high
risk
subsequ
lung
infect
nosocomi
organ
sever
infect
commonli
encount
treat
clear
transplant
periton
must
clear
surgeri
infect
periton
dialysi
cathet
remov
urinari
tract
infect
must
elimin
antibiot
without
nephrectomi
similarli
skin
diseas
threaten
integr
primari
defens
infect
correct
even
requir
initi
immunosuppress
eg
treat
psoriasi
eczema
transplant
final
histori
one
episod
diverticul
trigger
evalu
determin
whether
colectomi
indic
transplant
among
import
consider
transplant
recipi
strongyloidiasi
tuberculosi
aid
strongyloid
hyperinfect
syndrom
hemorrhag
enterocol
pneumonia
gramneg
polymicrob
bacteremia
mening
may
occur
year
transplant
patient
endem
area
screen
strongyloidesseroposit
recipi
empir
treat
ivermectin
pretranspl
prevent
activ
diseas
transplant
incid
activ
dissemin
tuberculosi
higher
transplant
recipi
gener
popul
major
antitubercul
drug
potenti
hepatotox
significantli
interact
immunosuppress
agent
thu
erad
tuberculosi
transplant
candid
transplant
prefer
patient
greater
risk
tuberculosi
infect
exposur
includ
individu
prior
histori
activ
tuberculosi
signific
sign
old
tuberculosi
chest
radiograph
recent
tuberculin
reaction
convers
known
exposur
activ
diseas
proteincalori
malnutrit
cirrhosi
immunodefici
exposur
relat
live
condit
eg
shelter
group
hous
ppdposit
individu
endem
region
highrisk
exposur
screen
activ
diseas
treat
present
latent
infect
therapi
initi
transplant
although
judgment
may
use
optim
time
latent
treatment
hiv
infect
gener
convert
progress
fatal
diseas
chronic
infect
control
complex
regimen
antivir
agent
highli
activ
antiretrovir
therapi
haart
prehaart
era
organ
transplant
gener
associ
rapid
progress
aid
kidney
transplant
hivinfect
recipi
associ
good
outcom
individu
control
hiv
infect
treatment
hcv
coinfect
transplant
haart
must
continu
despit
multipl
reciproc
drug
interact
antiretrovir
immunosuppress
medic
necessit
experi
hiv
transplant
drug
manag
reject
occur
frequent
host
standard
intens
immunosuppress
requir
signific
interact
calcineurin
mammalian
target
rapamycin
mtor
inhibitor
hiv
proteas
inhibitor
pi
nonnucleosid
analog
revers
transcriptas
inhibitor
nnrti
via
hepat
cytochrom
system
pglycoprotein
adjust
dosag
dose
interv
immunosuppress
medic
requir
drug
level
toxic
must
monitor
close
drug
eg
raltegravir
fewer
interact
cc
chemokin
receptor
type
receptor
antagonist
maraviroc
may
even
decreas
rate
graft
reject
vitro
antiretrovir
synergi
occur
sirolimu
earlier
antagonist
use
sirolimusbas
immunosuppress
may
increas
rate
graft
reject
prophylaxi
p
jirovecii
pneumonia
pjp
toxoplasmosi
seroneg
recipi
seroposit
organ
continu
life
prefer
use
tmpsmx
spectrum
infect
immunocompromis
host
broad
given
potenti
toxic
antimicrobi
agent
need
rapid
interrupt
infect
earli
specif
diagnosi
essenti
popul
wherea
initi
empir
therapi
broad
necess
rapid
narrow
antimicrobi
spectrum
data
becom
avail
essenti
advanc
diagnost
modal
eg
ct
magnet
reson
imag
molecular
microbiolog
techniqu
highthroughput
sequenc
greatli
assist
process
need
invas
procedur
overemphas
often
requir
specif
microbiolog
diagnosi
key
among
decis
antiinfect
therapi
whether
reduc
intens
immunosuppress
understand
risk
approach
graft
reject
andor
aggress
sometim
detriment
inflammatori
respons
immun
reconstitut
inflammatori
syndrom
iri
perhap
best
demonstr
patient
cryptococc
mening
rebound
inflammatori
respons
may
result
worsen
symptom
hydrocephalu
despit
appropri
antimicrobi
therapi
latent
viral
infect
tuberculosi
activ
evid
excess
immunosuppress
rel
host
immun
function
contrast
intercurr
bacteri
fungal
infect
reduct
immunosuppress
might
revers
resolut
infect
demonstr
specif
reduct
chosen
may
depend
organ
isol
eg
corticosteroid
bacteri
infect
similarli
revers
immun
deficit
eg
neutropenia
hypogammaglobulinemia
may
possibl
adjunct
therapi
eg
colonystimul
factor
antibodi
therapi
final
coinfect
immunoregulatori
virus
cmv
common
activ
infect
screen
treat
invas
infect
result
cmv
becom
less
common
avail
effect
antivir
therapi
diagnost
monitor
assay
viru
see
tabl
even
latent
infect
lowlevel
replic
import
implic
transplant
outcom
strategi
use
prevent
univers
versu
preemptiv
therapi
treat
infect
vari
center
manifest
cmv
infect
tradit
term
direct
indirect
effect
accur
term
might
viremiccytopath
effect
cellularimmunolog
effect
common
direct
effect
clinic
syndrom
includ
cmv
syndrom
viremia
associ
fever
neutropenia
variabl
associ
featur
infecti
mononucleosi
includ
hepat
nephriti
lymphaden
leukopenia
andor
thrombocytopenia
pneumon
often
difficult
distinguish
appar
benign
secret
gastrointestin
invas
esophag
coliti
gastriti
ulcer
bleed
perfor
hepat
pancreat
myocard
meningoenceph
hemolyt
urem
syndrom
microangiopath
thrombosi
chorioretin
central
nervou
system
cn
vascul
enceph
direct
clinic
manifest
cmv
infect
usual
occur
month
transplant
absenc
prophylaxi
chorioretin
chorioretin
occur
low
level
viral
replic
gener
later
posttranspl
cours
viremia
symptomat
infect
rare
effect
antivir
prophylaxi
cmv
activ
may
develop
despit
prophylaxi
intensif
immunosuppress
eg
reject
cellular
immunolog
effect
cmv
infect
discuss
later
result
suppress
varieti
host
defens
mechan
predispos
secondari
invas
p
jirovecii
candida
aspergillu
speci
bacteri
fungal
pathogen
cmv
infect
also
contribut
risk
graft
reject
ptld
acceler
hcv
coinfect
infect
increas
risk
death
primari
cmv
infect
greatest
risk
cmv
infect
set
seroneg
individu
receiv
graft
latent
infect
seroposit
donor
reactiv
viru
within
graft
patient
becom
virem
absenc
prophylaxi
often
without
symptom
mani
becom
virem
cessat
antivir
prophylaxi
symptomat
late
infect
occur
onethird
recipi
previous
treat
prophylaxi
primari
cmv
infect
often
sever
may
also
occur
seroneg
individu
children
transfus
via
sexual
contact
commun
allograft
may
privileg
site
viral
replic
mhcrestrict
virusspecif
cytotox
cell
decreas
abil
elimin
viral
infect
cell
presenc
donor
recipi
mhc
mismatch
reactiv
infect
seroposit
individu
reactiv
endogen
viru
transplant
convent
immunosuppress
therapi
use
without
antilymphocyt
antibodi
induct
treatment
approxim
experi
direct
cmv
syndrom
absenc
prophylaxi
higher
rate
cell
deplet
therapi
cmv
superinfect
viru
deriv
seroposit
donor
may
reactiv
seroposit
recipi
dr
blood
transfus
even
leukocytereduc
low
rate
transmiss
cmv
infect
observ
gain
import
patient
requir
signific
transfus
periop
set
multipl
factor
may
drive
cmv
activ
includ
intens
immunosuppress
notabl
pulseddos
corticosteroid
amount
viru
graft
use
lytic
celldeplet
therapi
coinfect
herpesvirus
graft
reject
event
share
featur
inflamm
fever
endotheli
activ
injuri
secret
proinflammatori
cytokin
includ
tumor
necrosi
activ
intracellular
transloc
cell
nucleu
activ
cmv
major
immediateearli
promoterenhanc
viral
replic
risk
viral
activ
graft
reject
promin
combin
alloimmun
respons
produc
graft
inflamm
injuri
gener
site
greatest
viral
load
mhc
mismatch
intensif
immunosuppress
system
inflamm
fever
enhanc
mhc
display
allograft
thu
bidirect
linkag
exist
cmv
replic
graft
reject
reink
et
al
show
patient
biopsi
evid
late
acut
reject
demonstr
respons
antivir
therapi
similarli
lowanc
colleagu
demonstr
prevent
cmv
infect
also
result
lower
incid
graft
reject
cellular
immunolog
effect
cmv
indirect
effect
import
immunocompromis
host
invas
viral
infect
mechan
effect
complex
relat
viral
strategi
evad
host
respons
allow
cmvinfect
antigenpres
cell
travel
throughout
host
spread
viru
clinic
manag
cmv
includ
prevent
treatment
base
understand
caus
cmv
activ
avail
diagnost
techniqu
cmv
cultur
longer
essenti
resist
test
perform
molecular
sequenc
posit
cmv
cultur
shell
vial
cultur
deriv
respiratori
secret
urin
littl
diagnost
valuemani
immunosuppress
patient
secret
cmv
absenc
invas
diseas
serolog
test
use
transplant
predict
risk
littl
valu
transplant
defin
clinic
diseas
seroconvers
gener
delay
seroconvers
posit
cmv
igg
provid
evid
patient
develop
degre
immun
appear
correl
gener
cell
function
quantit
intens
cmv
viral
burden
link
risk
infect
transplant
recipi
two
type
quantit
assay
develop
molecular
antigen
detect
assay
antigenemia
assay
laborintens
semiquantit
less
commonli
use
nat
circul
neutrophil
immunostain
cmv
earli
antigen
taken
nonspecif
measur
total
viral
burden
qnat
gener
use
diagnosi
preemptiv
manag
strategi
monitor
respons
therapi
cmv
deoxyribonucl
acid
dna
gener
detect
earlier
whole
blood
compar
plasma
one
specimen
type
one
laboratori
use
monitor
patient
highest
viral
load
often
associ
tissueinvas
diseas
lowest
associ
asymptomat
cmv
infect
multipl
viral
strain
often
present
infect
viral
load
present
cmv
syndrom
vari
wide
singl
quantit
assay
use
consist
monitor
patient
world
health
organ
intern
refer
standard
becam
avail
clinic
isol
merlin
titer
iuml
laboratori
test
calibr
intern
standard
result
report
iuml
one
sourc
variabl
differ
dna
extract
method
multipl
viral
genotyp
may
observ
often
patient
sever
diseas
antivir
resist
resist
test
perform
face
poor
clinic
virolog
respons
adequ
therapi
least
day
respons
may
delay
highlevel
viremia
multipl
risk
factor
drug
resist
often
coexist
includ
prolong
antivir
drug
exposur
notabl
inadequ
dose
lack
immun
highlevel
viral
replic
intens
immunosuppress
advent
quantit
assay
diagnosi
manag
cmv
infect
allow
noninvas
diagnosi
mani
patient
two
import
except
neurolog
diseas
includ
chorioretin
gastrointestin
diseas
includ
invas
coliti
gastriti
syndrom
cmv
viral
load
often
low
detect
limit
diagnosi
gastrointestin
cmv
diseas
demonstr
cmv
inclus
tissu
andor
immunohistolog
cmv
antigen
remain
essenti
central
role
assay
illustr
approach
manag
cmv
risk
see
tabl
schedul
screen
link
risk
infect
highrisk
patient
r
antilymphocyt
globulin
complet
prophylaxi
monthli
screen
perform
ensur
absenc
viremia
month
patient
treat
cmv
infect
assay
provid
endpoint
therapi
initi
prophylaxi
prevent
cmv
infect
must
individu
immunosuppress
regimen
patient
see
tabl
two
strategi
commonli
use
cmv
preventionunivers
prophylaxi
preemptiv
therapi
univers
prophylaxi
involv
give
antivir
therapi
atrisk
patient
transplant
defin
period
preemptiv
therapi
qnat
assay
use
monitor
patient
predefin
interv
gener
weekli
week
detect
earli
diseas
posit
assay
result
therapi
preemptiv
therapi
incur
extra
cost
monitor
coordin
outpati
care
reduc
cost
drug
inher
toxic
prophylaxi
possibl
advantag
prevent
cmv
infect
period
greatest
risk
also
diminish
infect
secondari
ebv
indirect
effect
cmv
ie
graft
reject
herpesviru
infect
opportunist
infect
also
may
reduc
routin
prophylaxi
practic
neither
univers
prophylaxi
preemptiv
therapi
perfect
mani
center
use
combin
approach
univers
prophylaxi
highestrisk
recipi
r
cell
deplet
preemptiv
therapi
other
infrequ
breakthrough
diseas
ganciclovir
resist
observ
approach
given
risk
invas
infect
patient
risk
primari
infect
donor
cmv
seroposit
patient
receiv
deplet
antitlymphocyt
antibodi
gener
given
prophylaxi
month
transplant
group
candid
preemptiv
therapi
appropri
monitor
system
place
patient
complianc
good
current
data
support
use
univers
prophylaxi
preemptiv
therapi
prevent
indirect
effect
cmv
infect
includ
ptld
opportunist
infect
allograft
reject
mortal
increasingli
late
diseas
observ
complet
prophylaxi
thu
monitor
may
use
prophylaxi
rate
late
diseas
vari
thought
high
recipi
support
valu
prophylaxi
month
renal
recipi
impact
studi
option
cmv
prophylaxi
includ
valganciclovir
mg
oral
daili
oral
ganciclovir
g
three
time
daili
intraven
ganciclovir
mgkg
daili
highdos
oral
valacyclovir
g
four
time
daili
correct
renal
function
valganciclovir
ganciclovir
associ
neutropenia
howev
dose
reduct
risk
breakthrough
viremia
emerg
viral
resist
given
chang
renal
function
transplant
cost
medic
mani
regimen
employ
lower
dose
valganciclovir
regimen
coupl
monitor
assur
efficaci
complet
treatment
cmv
diseas
see
later
mani
center
initi
cours
secondari
prophylaxi
month
altern
strategi
virolog
monitor
period
treatment
standard
care
treat
invas
cmv
diseas
week
intraven
iv
ganciclovir
mgkg
twice
daili
dosag
adjust
renal
dysfunct
quantit
assay
cmv
neg
patient
mild
moder
sever
symptom
valganciclovir
mg
oral
twice
daili
correct
renal
function
may
use
altern
symptomat
patient
slow
respond
therapi
seroneg
addit
cmv
hyperimmun
globulin
mg
kgdose
iv
monthli
month
controversi
costli
uncertain
benefit
relaps
occur
primarili
seroneg
patient
high
viral
burden
treat
achiev
neg
quantit
assay
gastrointestin
diseas
treat
oral
regimen
repeat
endoscopi
may
consid
poor
clinic
respons
process
present
ischemia
cancer
practic
reason
initi
therapi
intraven
ganciclovir
monitor
weekli
assur
virolog
respons
treat
monitor
neg
often
two
neg
weekli
assay
patient
may
benefit
month
oral
valganciclovir
mg
daili
base
creatinin
clearanc
administ
secondari
prophylaxi
complet
intraven
therapi
approach
result
rare
symptomat
relaps
associ
uncommonli
emerg
antivir
resist
may
worth
measur
formal
creatinin
clearanc
assur
adequ
dose
incid
ganciclovir
resist
cmv
gener
low
risk
resist
greatest
recipi
higher
viral
load
receiv
inadequ
dose
prophylact
therapeut
ganciclovir
intens
immunosuppress
includ
antilymphocyt
antibodi
induct
prolong
antivir
prophylaxi
clinic
patient
viral
load
clinic
syndrom
fail
respond
appropri
therapi
includ
reduct
immunosuppress
day
genet
resist
test
use
manag
resist
cmv
infect
mani
mutat
identifi
includ
mutat
viral
thymidin
kinas
dna
polymeras
gene
confer
ganciclovir
resist
common
mutat
gene
respond
higher
dose
intraven
ganciclovir
combin
mutat
may
manifest
highlevel
resist
ganciclovir
altern
therapi
avail
intraven
form
includ
foscarnet
cidofovir
foscarnet
activ
mani
ganciclovirresist
strain
cmv
although
associ
mark
magnesium
potassium
wast
seizur
notabl
calcineurin
inhibitor
therapi
renal
toxic
cidofovir
may
also
use
often
incur
signific
nephrotox
ocular
toxic
viral
polymeras
mutat
may
caus
resist
foscarnet
cidofovir
depend
natur
mutat
multipl
cours
antivir
therapi
may
need
cure
resist
cmv
infect
given
toxic
avail
medic
newer
drug
becom
avail
new
agent
letermovir
demonstr
promis
manag
cmv
infect
stem
cell
transplant
recipi
letermovir
appear
good
oral
bioavail
low
rate
advers
effect
drugdrug
interact
letermovir
exert
antivir
effect
interf
viral
gene
product
disrupt
viral
terminas
complex
addit
hyperimmun
globulin
may
benefici
center
tri
reduc
overal
immunosuppress
therapi
altern
agent
includ
dihydroorot
dehydrogenas
inhibitor
leflunomid
approv
immunosuppress
treatment
rheumatolog
diseas
use
incident
activ
cmv
possibl
bk
polyomaviru
effect
use
requir
monitor
drug
level
liver
function
test
phase
iii
trial
maribavir
competit
inhibitor
protein
appear
safe
efficaci
cmv
prevent
suboptim
broadspectrum
oral
lipid
antivir
conjug
cidofovir
activ
adenoviru
well
cmv
drug
good
bioavail
doselimit
diarrhea
ebv
ubiquit
herpesviru
infect
b
lymphocyt
immunosuppress
transplant
recipi
primari
ebv
infect
relaps
absenc
antivir
immun
caus
mononucleosistyp
syndrom
gener
manifest
lymphocytosi
b
cell
without
lymphadenopathi
pharyng
mening
hepat
pancreat
also
observ
remittingrelaps
ebv
infect
common
children
may
reflect
interplay
evolv
antivir
immun
immunosuppress
regardless
mode
express
syndrom
suggest
rel
overimmunosuppress
ebv
also
play
central
role
pathogenesi
ptld
ptld
repres
spectrum
diseas
benign
b
cell
mononucleosislik
syndrom
monomorph
b
cell
lymphoma
tumor
cell
natur
killer
cell
nullcel
origin
fig
clearli
defin
risk
factor
ptld
primari
ebv
infect
increas
risk
ptld
ptld
may
occur
absenc
ebv
infect
seroposit
patient
role
ebv
pathogenesi
nonb
cell
tumor
less
clear
risk
factor
includ
cmv
coinfect
cell
deplet
therapi
durat
immunosuppress
adult
older
age
lymphoma
constitut
tumor
among
adult
transplant
recipi
children
mortal
mani
death
associ
allograft
failur
withdraw
immunosuppress
treatment
malign
compar
gener
popul
ptld
increas
extranod
involv
poor
respons
convent
therapi
poor
outcom
spectrum
diseas
broad
note
previous
ebvneg
ptld
describ
cell
ptld
shown
allograft
thought
reject
viral
infect
ptld
late
year
transplant
often
ebvneg
adult
clinic
present
ebvassoci
ptld
vari
wide
includ
unexplain
fever
fever
unknown
origin
viremia
mononucleosistyp
syndrom
fever
malais
without
pharyng
tonsil
often
diagnos
incident
tonsillectomi
specimen
often
lymphadenopathi
observ
gastrointestin
bleed
obstruct
perfor
abdomin
mass
lesion
infiltr
diseas
allograft
hepatocellular
pancreat
dysfunct
cn
mass
lesion
diagnosi
serolog
test
use
diagnosi
acut
ebv
infect
ptld
transplant
quantit
ebv
viral
load
test
requir
diagnosi
manag
ebvposit
ptld
serial
assay
use
individu
patient
specif
viral
load
measur
data
suggest
assay
use
unfraction
whole
blood
prefer
plasma
sampl
ebv
viral
load
surveil
diagnosi
ptld
may
suggest
presenc
compat
clinic
syndrom
demonstr
ebv
viral
load
standard
exist
ebv
viral
load
assay
howev
assay
directli
compar
laboratori
given
laboratoryspecif
differ
perform
trend
individu
patient
time
use
singl
assay
use
demonstr
ebvspecif
nucleic
acid
tissu
may
diagnos
ebvassoci
ptld
rna
situ
hybrid
ebvencod
small
nuclear
rna
sensit
detect
viral
dna
ebvlat
antigen
detect
immunohistochemistri
clinic
manag
depend
stage
diseas
polyclon
form
particularli
children
reestablish
immun
function
may
suffic
caus
ptld
regress
stage
possibl
antivir
therapi
might
util
given
viremia
role
ebv
cmv
present
immunosuppress
agent
progress
diseas
extranod
monoclon
malign
form
reduct
immunosuppress
may
use
altern
therapi
often
requir
kidney
transplant
failur
regress
signific
reduct
immunosuppress
may
suggest
need
sacrific
allograft
patient
surviv
combin
antib
cell
therapi
rituximab
chemotherapi
chop
cyclophosphamid
hydroxydaunomycin
vincristin
prednison
irradi
especi
cn
tumor
adopt
immunotherapi
stimul
cell
use
polyomavirus
polyomavirus
identifi
transplant
recipi
associ
tubulointerstiti
nephriti
nephropathi
pyvan
bk
viru
bkv
jc
viru
jcv
ureter
stenosi
bkv
associ
demyelin
diseas
brain
jcvassoci
progress
multifoc
leukoencephalopathi
pml
less
commonli
polyomavirus
identifi
associ
trichodysplasia
spinulosa
tsv
malign
merkel
cell
carcinoma
mcv
condyloma
tissu
receptor
human
virus
ubiquit
seropreval
adult
polyomavirus
rang
bkv
resid
latenc
renal
tubular
epitheli
cell
jcv
also
isol
renal
tissu
prefer
tropism
neural
tissu
reactiv
occur
immunodefici
immunosuppress
tissu
injuri
eg
ischemiareperfus
bkv
associ
rang
clinic
syndrom
immunocompromis
host
includ
viruria
viremia
ureter
ulcer
stenosi
hemorrhag
cystiti
activ
infect
renal
allograft
associ
progress
loss
graft
function
bkv
nephropathi
approxim
rang
kidney
transplant
recipi
refer
pyvan
polyomavirusassoci
nephropathi
bkv
nephropathi
rare
recogn
recipi
extraren
organ
clinic
present
diseas
usual
asymptomat
steril
pyuria
reflect
shed
infect
tubular
ureter
epitheli
cell
cell
contain
sheet
viru
detect
urin
cytolog
decoy
cell
case
patient
present
diminish
renal
allograft
function
ureter
stenosi
obstruct
patient
etiolog
decreas
renal
function
must
care
evalu
eg
mechan
obstruct
drug
toxic
pyelonephr
reject
thrombosi
recurr
diseas
choic
must
made
increas
immunosuppress
treat
suspect
graft
reject
reduc
immunosuppress
allow
immun
system
control
infect
patient
bkv
nephropathi
treat
increas
immunosuppress
high
incid
graft
loss
reduc
immunosuppress
may
stabil
renal
allograft
function
risk
graft
reject
clinic
syndrom
may
associ
bkv
includ
pneumon
hemophagocyt
syndrom
enceph
pml
risk
factor
bkv
nephropathi
includ
highdos
immunosuppress
particularli
cell
deplet
tacrolimu
mycophenol
mofetil
pulsedos
steroid
treatment
presum
graft
reject
ischemiareperfus
injuri
increas
number
human
leukocyt
antigen
hla
mismatch
donor
recipi
intens
viremia
pathogenesi
diseas
renal
retransplant
pyvan
risk
factor
reinfect
jcv
may
also
caus
nephropathi
role
specif
immunosuppress
agent
confirm
greatest
incid
bkv
nephropathi
center
intens
immunosuppress
regimen
pyvan
reflect
rise
serum
creatinin
center
develop
screen
program
document
earli
diseas
use
urin
cytolog
detect
presenc
infect
decoy
cell
urin
high
sensit
bkv
infect
low
predict
valu
pyvan
detect
urin
bkv
electron
microscopi
urin
bkv
viral
dna
load
greater
log
geqml
bkv
gene
mrna
log
copiesng
total
urin
rna
use
diagnost
keep
mind
bkv
molecular
test
vari
depend
target
matrix
test
patient
bkv
nephropathi
tend
higher
plasma
viral
load
one
studi
bkv
copi
per
ml
plasma
p
posit
predict
valu
neg
predict
valu
compar
patient
without
diseas
high
serum
bkv
viral
load
consid
basi
reduct
immunosuppress
especi
serum
creatinin
risen
diagnosi
made
demonstr
bkv
cytopath
chang
cellular
infiltr
consist
diagnosi
interstiti
nephriti
allograft
immunohistolog
bkv
protein
situ
hybrid
bkv
nucleic
acid
renal
biopsi
semiquantit
score
system
histolog
chang
pyvan
immunohistochemistri
crossreact
antibodi
larg
antigen
simian
viru
antibodi
agnoprotein
use
pyvan
character
intranuclear
polyomaviru
inclus
bodi
tubular
epitheli
andor
glomerular
cell
fibrosi
often
promin
occasion
calcif
pyvan
often
focal
falseneg
biopsi
case
graft
reject
may
accompani
pyvan
complic
diagnosi
manag
recommend
regard
screen
bkv
infect
vari
gener
suggest
test
everi
month
first
year
transplant
least
annual
year
urinari
test
bkv
cytolog
decoy
cell
urin
bkv
viral
load
log
geqml
adequ
screen
patient
high
urinari
bkv
viral
load
requir
test
plasma
bkv
dna
screen
also
perform
use
plasma
bkv
dna
load
patient
plasma
bkv
dna
load
geqml
duplic
test
week
apart
presumpt
diagnosi
pyvan
made
immunosuppress
reduc
see
later
screen
perform
plasma
viral
load
interv
screen
assay
reduc
monthli
first
month
posttranspl
reflect
faster
onset
perman
renal
injuri
patient
circul
viremia
compar
urinari
excret
treatment
accept
treatment
pyvan
reduct
intens
immunosuppress
use
monitor
respons
maneuv
use
plasma
viral
load
measur
despit
controversi
reason
reduc
dose
calcineurin
inhibitor
antimetabolit
stepwis
fashion
monitor
bkv
plasma
load
given
toxic
calcineurin
inhibitor
tubular
cell
role
renal
tubular
injuri
activ
bkv
need
antibkv
cell
activ
agent
includ
initi
reduct
gener
target
includ
tacrolimu
trough
level
ngml
cyclosporin
trough
level
ngml
sirolimu
trough
level
ngml
andor
mycophenol
mofetil
daili
dose
equival
mg
regardless
approach
renal
function
least
time
per
week
drug
level
viral
load
altern
week
must
monitor
care
reduct
rebiopsi
may
need
poor
virolog
clinic
respons
use
adjunct
antivir
therapi
remain
controversi
center
advoc
use
cidofovir
without
probenecid
bkv
nephropathi
low
dose
mgkg
everi
week
signific
renal
toxic
may
observ
cidofovir
despit
probenecid
may
decreas
efficaci
leflunomid
immunosuppress
use
rheumatoid
arthriti
fluoroquinolon
antibkv
activ
vitro
littl
efficaci
vivo
replet
serum
immunoglobulin
may
consid
retransplant
success
pyvan
patient
fail
allograft
possibl
reflect
immun
develop
reduct
immunosuppress
center
allow
retransplant
immunosuppress
discontinu
period
eg
month
bkv
undetect
blood
low
urin
surgic
remov
allograft
protect
futur
bkv
infect
pyvan
may
need
immunosuppress
reduc
doubl
transplant
allosensit
andor
elev
viral
load
persist
futur
measur
bkvspecif
cellular
immun
discontinu
immunosuppress
may
help
determin
optim
time
retransplant
infect
cn
jc
polyomaviru
observ
uncommonli
transplant
recipi
pml
see
fig
infect
may
present
focal
neurolog
deficit
seizur
slowli
progress
neurolog
lesion
may
progress
death
extens
demyelin
pml
may
confus
calcineurin
neurotox
may
respond
reduct
drug
level
proven
therapi
exist
although
reduct
immunosuppress
commonli
employ
analog
immun
reconstitut
aid
patient
pml
human
papillomaviru
hpv
infect
associ
anogenit
skin
precanc
cancer
wart
b
associ
human
hpv
infect
anogenit
wart
consid
marker
possibl
carriag
risk
type
cervic
anal
cancer
includ
routin
gynecolog
skin
screen
mandatori
transplant
recipi
success
organ
transplant
hivinfect
individu
discuss
earlier
achiev
effect
antiretrovir
therapi
full
transplant
immunosuppress
includ
appropri
cell
deplet
therapi
reject
rate
remain
higher
nonhivinfect
group
manag
requir
care
track
immunosuppress
drug
level
avoid
proteas
inhibitor
antiretrovir
therapi
art
select
possibl
knowledg
hiv
suscept
pattern
prophylaxi
opportunist
infect
depend
epidemiolog
individu
eg
mycobacteria
coccidioid
histoplasma
exposur
routin
therapi
donor
hiv
hcv
infect
use
center
expertis
antivir
manag
transplant
transplant
recipi
risk
opportunist
infect
varieti
fungal
pathogen
import
candida
aspergillu
cryptococcu
neoforman
also
includ
endem
mycos
common
fungal
pathogen
transplant
patient
candida
nonalbican
speci
mucocutan
candid
infect
eg
oral
thrush
esophag
infect
cutan
infect
intertrigin
site
candid
vagin
common
diabet
highdos
steroid
therapi
broadspectrum
antibacteri
therapi
infect
usual
treatabl
correct
underli
metabol
abnorm
topic
therapi
clotrimazol
nystatin
see
tabl
thrush
also
may
complic
viral
hsv
cmv
toxic
drug
includ
mycophenol
mofetil
esophag
optim
manag
candida
infect
occur
associ
surgic
drain
vascular
access
cathet
requir
remov
foreign
bodi
system
antifung
therapi
fluconazol
echinocandin
singl
posit
blood
cultur
result
candida
speci
necessit
system
antifung
therapi
find
carri
signific
risk
dissemin
popul
special
problem
kidney
transplant
recipi
candiduria
includ
asymptomat
patient
notabl
individu
poor
bladder
function
obstruct
fungal
ball
develop
ureteropelv
junction
result
obstruct
uropathi
ascend
pyelonephr
possibl
system
dissemin
invas
aspergillosi
medic
emerg
transplant
recipi
portal
entri
lung
sinus
patient
skin
other
predomin
speci
depend
clinic
center
prior
azol
exposur
patholog
hallmark
invas
aspergillosi
blood
vessel
invas
account
three
clinic
characterist
infectiontissu
infarct
hemorrhag
system
dissemin
metastat
invas
soon
transplant
cn
fungal
infect
often
result
aspergillu
year
later
transplant
fungi
mucoral
dematiac
fungi
becom
promin
drug
choic
document
aspergillu
infect
voriconazol
despit
signific
interact
calcineurin
inhibitor
rapamycin
isavuconazol
azol
antifung
activ
yeast
aspergillu
mucoral
shown
safe
efficaci
solidorgan
transplant
recipi
although
may
requir
dose
adjust
therapeut
drug
monitor
immunosuppress
agent
liposom
amphotericin
effect
fungicid
altern
though
toxic
altern
renal
transplant
reserv
case
azol
contraind
toler
although
toxic
amphotericin
b
prepar
echinocandin
use
situat
azol
polyen
antifung
contraind
recommend
primari
therapi
invas
aspergillosi
includ
renal
infect
combin
therapi
use
voriconazol
anidulafungin
studi
hematolog
malign
popul
show
surviv
advantag
surgic
debrid
sometim
requir
success
clearanc
invas
infect
cn
infect
transplant
recipi
may
result
broad
spectrum
organ
infect
often
metastat
cn
blood
lung
viral
etiolog
includ
cmv
nodular
angiiti
hsv
meningoenceph
jcv
progress
multifoc
leukoencephalopathi
vzv
local
epidem
pathogen
wnv
eastern
equin
enceph
also
must
consid
bacteri
pathogen
includ
pneumonia
borrelia
burgdorferi
lyme
diseas
l
monocytogen
tuberculosi
nocardia
occasion
salmonella
brain
epidur
abscess
observ
may
particularli
problemat
secondari
antibioticresist
pathogen
note
earlier
fungi
may
metastat
lung
also
may
spread
sinus
skin
blood
parasit
potenti
cn
involv
includ
toxoplasma
gondii
strongyloid
stercorali
given
spectrum
etiolog
precis
diagnosi
essenti
tabl
reason
empir
regimen
would
treat
pneumococcu
haemophilu
influenza
ceftriaxon
vancomycin
listeria
ampicillin
cryptococcu
fluconazol
lipid
formul
amphotericin
hsv
acyclovir
await
data
lumbar
punctur
blood
cultur
radiograph
studi
noninfecti
etiolog
includ
calcineurin
inhibitooo
r
toxic
lymphoma
metastat
cancer
includ
differenti
diagnosi
molecular
hsv
vzv
toxoplasma
antigen
cryptococc
assay
cerebrospin
fluid
biopsi
noninfecti
etiolog
may
need
diagnosi
cryptococc
infect
rare
seen
transplant
recipi
month
transplant
rel
intact
transplant
recipi
common
present
cryptococc
infect
asymptomat
pulmonari
nodul
organ
present
chronic
neerdowel
patient
pneumonia
mening
common
skin
involv
site
tissu
injuri
cathet
prostat
bone
involv
also
report
cryptococcosi
suspect
transplant
recipi
present
month
transplant
unexplain
headach
especi
accompani
fever
decreas
state
conscious
failur
thrive
unexplain
focal
skin
diseas
requir
biopsi
cultur
patholog
evalu
diagnosi
often
achiev
serum
cryptococc
antigen
detect
patient
lumbar
punctur
cell
count
gram
stain
cultur
india
ink
prepar
cryptococc
antigen
studi
fig
initi
treatment
cn
diseas
liposom
amphotericin
monitor
serum
level
follow
highdos
fluconazol
extend
cours
fluconazol
suppress
may
requir
patient
base
clinic
progress
net
degre
immunosuppress
gradual
taper
immunosuppress
also
consid
initi
antifung
therapi
recogn
iri
clinic
manifest
mimic
worsen
cryptococc
diseas
may
occur
patient
reduct
immunosuppress
rapid
ultim
may
requir
adjunct
use
corticosteroid
iri
scar
may
caus
obstruct
increas
cerebrospin
fluid
pressur
hydrocephalu
strongyloid
stercorali
immunosuppress
therapi
stercorali
infect
may
activ
year
initi
exposur
reactiv
result
either
diarrheal
ill
parasit
migrat
hyperinfect
syndrom
character
hemorrhag
enterocol
hemorrhag
pneumonia
dissemin
infect
accompani
usual
gramneg
bacteremia
mening
immigr
refuge
travel
militari
personnel
station
hyperendem
region
includ
africa
asia
latin
america
caribbean
screen
strongyloid
igg
serolog
transplant
treat
ivermectin
preemptiv
seroposit
spectrum
potenti
pulmonari
pathogen
transplant
recipi
broad
gener
concept
worth
consider
depress
inflammatori
respons
immunocompromis
transplant
patient
may
greatli
modifi
delay
appear
pulmonari
lesion
radiograph
focal
multifoc
consolid
acut
onset
like
caus
bacteria
similar
multifoc
lesion
subacut
chronic
progress
like
secondari
fungi
tuberculosi
nocardia
larg
nodul
usual
sign
fungal
nocardia
infect
subacut
diseas
diffus
abnorm
either
peribronchovascular
type
miliari
micronodul
usual
caus
virus
especi
cmv
pneumocysti
addit
clue
found
examin
pulmonari
lesion
cavit
suggest
necrot
infect
may
caus
fungi
aspergillu
mucoracea
nocardia
staphylococcu
certain
gramneg
bacilli
commonli
klebsiella
pneumonia
pseudomona
aeruginosa
ct
chest
use
chest
radiograph
neg
radiograph
find
subtl
nonspecif
ct
also
essenti
determin
extent
diseas
process
discern
possibl
simultan
process
superinfect
select
optim
procedur
achiev
patholog
diagnosi
pneumocysti
pneumonia
risk
infect
pjp
greatest
first
month
transplant
without
tmpsmx
prophylaxi
period
increas
immunosuppress
continu
risk
infect
three
overlap
group
transplant
recipi
recipi
requir
higher
normal
level
immunosuppress
notabl
corticosteroid
prolong
period
poor
allograft
function
chronic
reject
recipi
chronic
cmv
infect
recipi
undergo
treatment
eg
cancer
chemotherapi
drug
toxic
increas
level
immunodefici
neutropenia
expect
mortal
secondari
pjp
increas
patient
cyclosporin
compar
immunocompromis
host
hallmark
pjp
presenc
mark
hypoxemia
dyspnea
cough
pauciti
physic
radiolog
find
transplant
recipi
pjp
gener
acut
subacut
develop
atyp
pneumocysti
infect
radiograph
clinic
may
seen
patient
coexist
pulmonari
infect
develop
diseas
receiv
prophylaxi
secondlin
agent
eg
pentamidin
atovaquon
patient
present
pjp
outsid
usual
highest
risk
period
may
indol
diseas
confus
radiograph
heart
failur
mtor
inhibitor
sirolimu
everolimu
also
associ
develop
interstiti
lung
diseas
confus
radiograph
clinic
pjp
two
casecontrol
studi
report
associ
use
sirolimu
develop
pjp
patient
invas
procedur
often
requir
definit
diagnosi
diagnosi
therapi
prophylaxi
characterist
hypoxemia
pjp
produc
broad
alveolararteri
partial
pressur
oxygen
gradient
level
serum
lactat
dehydrogenas
elev
patient
pjp
iuml
although
mani
diffus
pulmonari
process
also
increas
serum
lactat
dehydrogenas
level
diagnost
pattern
exist
pjp
routin
chest
radiograph
chest
radiograph
may
entir
normal
reveal
classic
pattern
perihilar
interstiti
groundglass
infiltr
see
fig
chest
ct
scan
sensit
diffus
interstiti
nodular
pattern
routin
radiograph
clinic
radiolog
manifest
pjp
virtual
ident
manifest
cmv
clinic
challeng
determin
whether
pathogen
present
bronchoalveolar
lavag
may
help
serum
base
test
show
excel
sensit
good
specif
diagnosi
pjp
signific
extrapulmonari
diseas
uncommon
transplant
recipi
earli
therapi
tmpsmx
prefer
kidney
transplant
patient
toler
fulldos
tmpsmx
prolong
period
reflect
elev
creatinin
trimethoprim
compet
secret
kidney
toxic
sulfa
agent
renal
allograft
hydrat
gradual
initi
therapi
may
help
altern
therapi
less
desir
use
success
includ
intraven
pentamidin
atovaquon
clindamycin
primaquin
pyrimethamin
trimetrex
use
short
cours
adjunct
steroid
gradual
taper
gener
use
import
prevent
pneumocysti
infect
overemphas
lowdos
tmpsmx
well
toler
use
absenc
concret
data
show
true
allergi
interstiti
nephriti
altern
prophylact
strategi
includ
dapson
atovaquon
inhal
intraven
pentamidin
less
effect
tmpsmx
use
patient
signific
allergi
sulfa
drug
advantag
tmpsmx
includ
increas
efficaci
lower
cost
avail
oral
prepar
possibl
protect
organ
includ
gondii
isospora
belli
cyclospora
cayetanensi
mani
nocardia
speci
common
urinari
respiratori
gastrointestin
bacteri
pathogen
altern
agent
lack
spectrum
activ
urinari
tract
infect
occur
first
year
kidney
transplant
subset
patient
experi
recurr
diseas
may
suffer
pyelonephr
bacteremia
urinari
tract
infect
beyond
month
transplant
associ
reduc
renal
graft
surviv
increas
mortal
risk
urinari
tract
infect
renal
transplant
increas
women
prolong
bladder
catheter
increas
intens
immunosuppress
recipi
deceas
donor
graft
possibl
vesicoureter
reflux
risk
vesicoureter
reflux
depend
part
surgic
approach
implant
uret
risk
candiduria
increas
patient
receiv
prior
antimicrobi
therapi
neurogen
bladder
indwel
urethr
cathet
intens
care
unit
kidney
transplant
recipi
bacteriuria
asymptomat
wherea
pain
pyelonephr
repres
transmur
infect
local
inflamm
outsid
denerv
allograft
caus
perceiv
allograft
tender
major
caus
organ
includ
gramneg
bacilli
escherichia
coli
klebsiella
pseudomona
enterobact
proteu
gramposit
larg
enterococci
fungi
candida
speci
group
may
manifest
import
antimicrobi
resist
therapi
base
suscept
pattern
presenc
absenc
structur
abnorm
obstruct
delay
bladder
empti
thu
cultur
imag
ultrasound
exclud
hydronephrosi
requir
patient
upper
tract
infect
initi
empir
therapi
includ
antimicrobi
agent
use
previous
prophylaxi
possibl
use
prior
episod
infect
given
risk
antimicrobi
resist
therapi
narrow
base
suscept
data
shortcours
therapi
use
treatment
uncompl
urinari
tract
infect
transplant
minimum
cours
effect
agent
recommend
upper
tract
diseas
pyelonephr
may
requir
intraven
therapi
initi
total
cours
clinic
respons
document
asymptomat
candiduria
treat
patient
renal
allograft
although
data
limit
fluconazol
mg
oral
per
day
day
upper
tract
diseas
candida
speci
suggest
obstruct
requir
intens
therapi
fluconazol
mg
daili
week
echinocandin
use
treatment
urinari
tract
infect
achiev
poor
concentr
urin
remov
stent
cathet
gener
requir
cure
prevent
urinari
tract
infect
alter
tmpsmx
prophylaxi
absenc
instrument
obstruct
tmpsmx
given
month
year
posttranspl
gener
effect
recent
studi
address
whether
chang
ecolog
bacteria
reduc
efficaci
prophylaxi
tmpsmx
intoler
patient
fluoroquinolon
may
use
prophylaxi
addit
anoth
agent
pjp
transplant
infecti
diseas
increasingli
character
abil
monitor
prevent
infect
base
prophylaxi
new
antimicrobi
agent
vaccin
despit
signific
advanc
infect
pose
lifethreaten
challeng
mani
recipi
futur
increas
avail
pathogenspecif
immun
function
test
enhanc
donor
recipi
screen
better
understand
infect
risk
genet
polymorph
combin
advanc
transplant
immunosuppress
reduc
infect
risk
